13 completed, 4 terminated, 1 not yet recruiting, 1 recruiting. 21 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 13, Terminated 4, Not yet recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Hydrochlorothiazide: new trials by email Literature Review of Hydrochlorothiazide trials Research Report on Hydrochlorothiazide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure Furosemide 40 Milligrams., Hydrochlorothiazide (HCTZ) 25 milligrams., Acetazolamide 250 milligrams. - Acute Heart Failure (AHF), Congestive Heart Failure Acute | Phase 2 / Phase 3 | Not yet recruiting | Hospital de Clinicas de Porto Alegre | 128 | 2026-03-23 | 2026-03-18 |
| Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention Indapamide 2.5 MG, Hydrochlorothiazide 50Mg, Chlorthalidone 25mg - Kidney Stone | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 99 | 2024-10-01 | 2026-05-06 |
| Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients Hydrochlorothiazide 50Mg, Placebos - Hypernatremia, Critical Illness | Phase 2 | Unknown | University of Sao Paulo | 184 | 2018-10-01 | 2019-04-30 |
| ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension Aerobic exercise, Perindopril, Losartan - Hypertension, Aging | Phase 2 | Completed | University of Alabama at Birmingham | 223 | 2018-05-29 | 2025-07-22 |
| Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism Teriparatide, Thiazide, Potassium sparing diuretic - Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2017-06-06 | 2021-06-28 |
| Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans Captopril Pill, Enalapril Pill, Hydrochlorothiazide - Hypertension,Essential | Phase 1 / Phase 2 | Terminated | Penn State University | 10 | 2016-07-20 | 2024-02-28 |
| The SCCS Polypill Pilot Trial Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide) - Hypertension, Hyperlipidemia | Phase 2 | Completed | Vanderbilt University | 303 | 2015-12-01 | 2021-05-14 |
| A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide Fimasartan, Hydrochlorothiazide, Placebo - Hypertension | Phase 2 | Completed | Boryung Pharmaceutical Co., Ltd | 103 | 2014-10-01 | 2016-07-01 |
| Vascular Dysfunction in Human Obesity Hypertension Clonidine, Hydrochlorothiazide, Placebo - Obesity, Prehypertension | Phase 2 | Terminated | Gary L. Pierce | 33 | 2013-10-01 | 2023-04-14 |
| Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension. TAK-536CCB, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide - Grade I or II Essential Hypertension | Phase 2 / Phase 3 | Completed | Takeda | 353 | 2013-03-01 | 2014-02-26 |
| Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension LCZ696, Olmesartan, LCZ696 matching placebo - Hypertension | Phase 2 | Completed | Novartis Pharmaceuticals | 454 | 2012-12-01 | 2016-05-04 |
| Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries Aliskiren vs. hydrochlorothiazide, Hydrochlorothiazide - Hypertension, Diabetes | Phase 2 | Withdrawn | Sir Mortimer B. Davis - Jewish General Hospital | 2012-01-01 | 2015-05-19 | |
| To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy Aliskiren, Placebo to Aliskiren, Hydrochlorothiazide (HCTZ) - Non-diabetic Nephropathy | Phase 2 | Terminated | Novartis Pharmaceuticals | 8 | 2011-01-01 | 2013-01-30 |
| A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension LCZ696, Amlodipine, Hydrochlorothiazide (HCTZ) - Essential Hypertension | Phase 2 | Completed | Novartis Pharmaceuticals | 341 | 2010-11-01 | 2015-10-21 |
| Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042) Placebo to Ertuglilflozin 1 or 5 mg, Ertugliflozin 1 mg, Ertugliflozin 5 mg - Diabetes Mellitus, Type 2, Hypertension | Phase 2 | Completed | Merck Sharp & Dohme LLC | 194 | 2010-05-17 | 2018-09-13 |
| Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes Dapagliflozin, Placebo, Hydrochlorothiazide - Type 2 Diabetes Mellitus | Phase 2 | Completed | AstraZeneca | 154 | 2009-10-01 | 2017-03-08 |
| The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial candesartan, lisinopril, hydrochlorothiazide - Cognitive Impairment, Hypertension | Phase 2 | Completed | University of Southern California | 53 | 2008-01-01 | 2013-02-15 |
| A Study in People With Mild Hypertension PPAR alpha, Hydrochlorothiazide, Placebo - Mild Hypertension | Phase 2 | Completed | Eli Lilly and Company | 153 | 2006-09-01 | 2007-05-15 |
| Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo Hydrochlorothiazide, Placebo, Candesartan - Hypertension, Obesity | Phase 2 | Completed | Umeå University | 26 | 2005-04-01 | 2008-10-16 |
| 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension Telmisartan, Hydrochlorothiazide, Telmisartan + Hydrochlorothiazide - Hypertension | Phase 2 | Completed | Boehringer Ingelheim | 583 | 2004-06-01 | 2013-11-08 |
Showing 20 of 21. Sign in to see all of them.
Hypertension (13) · Diabetes Mellitus, Type 2 (2) · Essential Hypertension (2) · Lymphoma, Follicular (2) · Nephrolithiasis (2) · Obesity (2) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Critical Illness (1) · Dent Disease (1) · Diabetes Mellitus (1) · Heart Failure (1) · Hypercalciuria (1) · Hyperlipidemias (1) · Hypernatremia (1)
Novartis Pharmaceuticals (3) · Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (1) · Boehringer Ingelheim (1) · Boryung Pharmaceutical Co., Ltd (1) · Eli Lilly and Company (1) · Gary L. Pierce (1) · Hospital de Clinicas de Porto Alegre (1) · Insel Gruppe AG, University Hospital Bern (1) · Merck Sharp & Dohme LLC (1) · Penn State University (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · Takeda (1) · Umeå University (1) · University of Alabama at Birmingham (1)
United States (7) · Japan (4) · France (3) · South Korea (3) · Brazil (2) · Canada (2) · Netherlands (2) · Sweden (2) · Taiwan (2) · Argentina (1) · China (1) · Colombia (1) · Germany (1) · Greece (1) · Italy (1)
Agnes Linglart, MD, PhD (1) · Anne Blanchard, MD, PhD (1) · Bret Goodpaster, PhD (1) · Daniel G Fuster, M.D. (1) · Ernesto L Schiffrin, MD, PhD (1) · Gary L Pierce, PhD (1) · Ihab Hajjar, MD (1) · Jan Eriksson, MD, PhD (1) · Lacy M Alexander, PhD (1)
PMID 17389151, PMID 18976849, PMID 22412114, PMID 23350899, PMID 24496699, PMID 25951755, PMID 31532959, PMID 32039215, PMID 34213819
2009 (1), 2016 (1), K23AG030057 (1), R01HL093238 (1)